An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 500
- 主要终点
- The incidence of pneumonia at 12 months
研究概览
简要总结
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients >=18 years of age;
- •Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
- •Never received pneumococcal vaccine
排除标准
- •Patients having other factors that preventing researchers from enrollment them.
研究组 & 干预措施
Vaccination group
Lung cancer patients receive 23-valent pneumonia vaccine
干预措施: 23-valent pneumococcal vaccine (Biological)
结局指标
主要结局
The incidence of pneumonia at 12 months
时间窗: 12 months
During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
Incidence of pneumonia
时间窗: 24 months
The proportion of lung cancer patients who developed pneumonia during the study period.
次要结局
- Survival rate(5 years)
研究者
Yalei Zhang
The First Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University